Appareil pulmonaire CheckMate 816 (CA209-816) Randomized, OpenLabel, Phase 3 Trial of Nivolumab and Ipilimumab Versus Platinum Doublet Chemotherapy in Early Stage NSCLC. Paris
Sarcomes EORTC-1447- STBSG Maintenance Therapy With Trabectedin Versus Observation After First Line Treatment With Doxorubicin of Patients With Advanced or Metastatic Soft Tissue Sarcoma. Paris SOPHIE PIPERNO-NEUMANN
Sein métastatique HER2+ HER2CLIMB (ONT-380-206) Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB) Paris
Appareil pulmonaire BR.31 (IFCT1401) A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer Paris
Sein métastatique HER2+ SOPHIA (CP-MGAH22-04) A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Prior Anti-HER2 Therapies and Require Systemic Treatment. Paris, Saint-Cloud ETIENNE BRAIN
VADS TOPNIVO - ORL09 A Safety study of Nivolumab in Patients with Recurrent and/or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN). Paris CHRISTOPHE LE TOURNEAU
Sein Néoadjuvant ULTIMATE A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant Paris, Saint-Cloud PAUL-HENRI COTTU, ETIENNE BRAIN
VADS UP-STREAM ( EORTC 1559-HNCG) A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. Paris CHRISTOPHE LE TOURNEAU
Appareil pulmonaire CANOPY-A (CACZ885T2301) A Phase III, Multicenter, Randomized, Double Blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Canakinumab Versus Placebo as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II -IIIA and IIIB (T>5cm N2) Completely Resected (R0) Non-small Cell Lung Cancer (NSCLC) Paris NICOLAS GIRARD
Appareil pulmonaire TET-SEL A Phase II Study of Selinexor (KPT-330) in Patients With Advanced Thymic Epithelial Tumour (TET) Progressing After Primary Chemotherapy. Paris NICOLAS GIRARD